Microbot Medical® to Participate at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference for The First Time
Rhea-AI Summary
Microbot Medical (Nasdaq: MBOT) will participate for the first time in the virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference, March 16-19, 2026.
CEO Harel Gadot will present a live webcast on March 19 at 8:40 am ET highlighting LIBERTY® limited market release progress, clinical experience, and growth drivers ahead of a planned full market release at SIR in April 2026.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
MBOT is up 2.94% while peers show mixed moves: KRMD (+3.36%), INFU (+4.73%), STXS (+1.97%) versus declines in AVR (-1.98%) and NYXH (-4.64%). No broad, one-directional sector move is indicated.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 04 | Radiation safety alignment | Positive | +2.5% | LIBERTY positioned as solution to AMA’s radiation protection policy with 92% reduction. |
| Mar 03 | Geopolitical stability | Positive | -3.6% | Company confirmed operational and commercial stability amid geopolitical events. |
| Feb 24 | Hospital adoption | Positive | +23.9% | Tampa General Hospital became first Florida health system to adopt LIBERTY. |
| Feb 19 | Conference feature | Positive | +2.4% | CEO featured at innovation summit panel showcasing LIBERTY and endovascular robotics. |
| Feb 12 | Conference highlight | Positive | +4.5% | LIBERTY highlighted at endovascular therapy conference, reinforcing FDA clearance and launch plans. |
Recent LIBERTY-focused news has generally been positive, with four of the last five announcements followed by positive price reactions, suggesting constructive responses to commercialization and visibility milestones.
Over the past month, MBOT has repeatedly highlighted its LIBERTY Endovascular Robotic System, emphasizing FDA clearance, limited market release in late 2025, and a planned full market release at the SIR conference in April 2026. News has included hospital adoption, conference showcases, and alignment with AMA radiation-safety policy. Most of these events produced positive one-day moves, with one geopolitical-stability update drawing a modest negative reaction. Today’s conference participation fits this ongoing commercialization and visibility narrative.
Regulatory & Risk Context
The company has an active S-3/A shelf filed on 2025-10-28, with effectiveness to occur under Section 8(a) of the Securities Act. The amendment mainly updated procedural language and expense details, and the shelf has been used at least 2 times via 424B3 filings dated 2025-11-19.
Market Pulse Summary
This announcement highlights Microbot Medical’s participation in a major medtech conference to showcase LIBERTY’s expanding clinical and commercial experience. It continues a series of updates on limited market release in late 2025 and a planned full market launch in April 2026. Recent history shows multiple LIBERTY-focused events and related SEC filings. Investors may watch how conference engagement translates into additional hospital adoption, procedure volume, and further regulatory or commercial milestones.
Key Terms
endovascular medical
robotic system medical
peripheral endovascular procedures medical
AI-generated analysis. Not financial advice.
Live Webcast on Thursday, March 19 at 8:40 am ET to Highlight the Expanding Clinical Experience with the LIBERTY® Endovascular Robotic System During the Limited Market Release
HINGHAM, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it will be participating at the virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference, held March 16-19, 2026. This marks the first time the Company has been invited to participate in this conference, reflecting growing market interest in the Company. Harel Gadot, CEO, President & Chairman will present live at 8:40 am ET on Thursday, March 19th. Mr. Gadot will highlight recent achievements from LIBERTY’s limited market release and review key market growth drivers that the Company believes will position itself to execute its near and long-term strategy to accelerate customer adoption and increase shareholder value. The presentation will be a live webcast and may be accessed via the ‘Investors’ section on Microbot Medical’s website at https://ir.microbotmedical.com/.
The Company’s Chief Financial Officer, Rachel Vaknin, and Earl Adamy, Vice President of Strategic Marketing & Business Development, will be available to meet institutional investors and other interested parties on Wednesday, March 18th. Interested parties should reach out to their Oppenheimer & Co. sales representatives or contact mpolyviou@evcgroup.com to schedule a one-on-one meeting with Microbot Medical’s management team.
“We continue to see that the progress and growing commercial momentum of LIBERTY’s limited market release is starting to generate meaningful interest at leading healthcare institutions. The Oppenheimer conference provides an important opportunity to share our milestones, emerging opportunities, and strategic initiatives with a broader audience,” commented Mr. Gadot. “We believe LIBERTY represents a unique and differentiated solution addressing critical unmet healthcare needs, and we have a unique opportunity as we create a new category of advanced surgical robotics designed to support the delivery of high-quality care.”
LIBERTY is the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, and it is designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain. The Company commenced the limited market release of the LIBERTY system in late 2025 and plans for a full market release at the Society of Interventional Radiology (SIR) conference in April 2026, allowing the Company to showcase LIBERTY with the goal to deepen market adoption.
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY® Endovascular Robotic System is the world’s first FDA cleared single-use, remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care.
Learn more at www.microbotmedical.com and connect on LinkedIn and X.
Safe Harbor
Statements to future financial and/or operating results, future adoption of products, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY® Endovascular Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical® disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Contacts:
IR@microbotmedical.com
Media@microbotmedical.com
FAQ
When will Microbot Medical (MBOT) present at the Oppenheimer conference and where can I watch the webcast?
Who will present for Microbot Medical (MBOT) at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference?
What will Microbot Medical (MBOT) discuss about the LIBERTY system at the March 19 presentation?
What is LIBERTY and what regulatory status does Microbot Medical (MBOT) state for it?
How can institutional investors schedule meetings with Microbot Medical (MBOT) during the Oppenheimer conference?
What are Microbot Medical's (MBOT) near-term commercialization plans for LIBERTY following the limited release?
